Resapp Health Ltd

ASX:RAP ISIN:AU000000RAP5

ResApp Health Limited (ASX:RAP)is engaged in developing digital healthcare solutions to assist doctors and patients to diagnose and manage respiratory disease. The Company offers a range of solutions, such as telehealth, clinical use, direct consumer and big data insights. The Company provides point of care diagnostic solutions for telehealth companies, which is integrated into their platforms. The Company is working on applications to provide clinical quality diagnostic tests and management tools directly to consumers and healthcare providers. The Company is developing smartphone medical applications for the diagnosis and management of respiratory disease. The Company's technology is based on the premise that cough and breathing sounds carry vital information on the state of the respiratory tract. ResApp measures the severity of a range of chronic and acute diseases, such as pneumonia, asthma, bronchiolitis and chronic obstructive pulmonary disease (COPD) using this insight.  
 

News

Aegis Equities Research Announce Health and Life Science Review, August 2006

🕔8/15/2006 2:42:55 PM 14361

The August 2006 edition of our Health & Life Science Quarterly Blue Book profiles niche life sciences companies, with a focus on company strategies, key projects and significant milestones.

Read Full Article
###

3,395 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 6) (Last 30 Days: 23) (Since Published: 3395) 

Company Data

    Headquarters
  • Level 24, 44 St Georges Terrace
    Perth WA 6000
    Australia
  • Telephone
  • +61-8-6211-5099 
  • Fax
  • +61-8-9218-8875 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology